Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2018

01-07-2018 | Original Article

MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer

Authors: Danyi Zhao, Yang Zhang, Lei Song

Published in: Pathology & Oncology Research | Issue 3/2018

Login to get access

Abstract

Chemotherapy can prevent metastasis and recurrence of gastric cancer (GC), and is a well supplement for operation. But, chemotherapy resistance has severely restricted the application of chemotherapy. This study aimed to investigate the regulatory roles and molecular mechanism of miR-16-1 to the chemosensitivity to adriamycin in GC. In this study, the expression of miR-16-1 and FUBP1 was down-regulated and up-regulated respectively in adriamycin-resistant GC tissues and cell lines, and represented a negative relationship between them. MiR-16-1 could silence FUBP1 directly and specifically, FUBP1 was a target gene of miR-16-1. Silence of FUBP1 inhibited the half maximal inhibitory concentration (IC50) of SGC7901/AR cell line to adriamycin, chemosensitivity enhanced significantly. Moreover, FUBP1 silence in SGC7901/AR cell line also inhibited proliferation and invasion, and advanced cell apoptosis. To sum up, the expression of miR-16-1 was positively related with the chemosensitivity of GC to adriamycin, and miR-16-1 could targeted silence FUBP1 to advance the chemosensitivity to adriamycin in GC, which might be a novel potential therapeutic target for GC.
Literature
1.
Sugano K (2015) Screening of gastric cancer in Asia. Best Pract Res Clin Gastroenterol 29(6):895–905CrossRefPubMed
2.
Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE (2015) Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol 6(5):534–543PubMedPubMedCentral
3.
Piletič K, Kunej T (2016) MicroRNA epigenetic signatures in human disease. Arch Toxicol 90(10):2405–2419CrossRefPubMed
4.
Mohammadi A, Mansoori B, Baradaran B (2016) The role of microRNAs in colorectal cancer. Biomed Pharmacother 84:705–713CrossRefPubMed
5.
Sekhon K, Bucay N, Majid S, Dahiya R, Saini S (2016) MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget 7(41):67597–67611CrossRefPubMedPubMedCentral
6.
Yang Y, Zhang P, Zhao Y, Yang J, Jiang G, Fan J (2016) Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer. Cancer Biol Ther 17(5):515–525CrossRefPubMed
7.
8.
9.
Wang W, Chen J, Dai J, Zhang B, Wang F, Sun Y (2016) MicroRNA-16-1 inhibits tumor cell proliferation and induces apoptosis in A549 non-small cell lung carcinoma cells. Oncol Res 24(5):345–351CrossRefPubMed
10.
Sam S, Sam MR, Esmaeillou M, Safaralizadeh R (2016) Effective targeting Survivin, caspase-3 and MicroRNA-16-1 expression by methyl-3-pentyl-6-methoxyprodigiosene triggers apoptosis in colorectal cancer stem-like cells. Pathol Oncol Res 22(4):715–723CrossRefPubMed
11.
Zhang C, Fang X, Li W, Shi Q, Wu L, Chen X, Huang Z, Wu P, Wang Z, Liao Z (2014) Influence of recombinant lentiviral vector encoding miR-15a/16-1 in biological features of human nasopharyngeal carcinoma CNE-2Z cells. Cancer Biother Radiopharm 29(10):422–427CrossRefPubMed
12.
Li X, Ling N, Bai Y, Dong W, Hui GZ, Liu D, Zhao J, Hu J (2013) MiR-16-1 plays a role in reducing migration and invasion of glioma cells. Anat Rec (Hoboken) 296(3):427–432CrossRef
13.
Cai CK, Zhao GY, Tian LY, Liu L, Yan K, Ma YL, Ji ZW, Li XX, Han K, Gao J, Qiu XC, Fan QY, Yang TT, Ma BA (2012) miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep 28(5):1764–1770CrossRefPubMed
14.
Wang T, Hou J, Li Z, Zheng Z, Wei J, Song D, Hu T, Wu Q, Yang JY, Cai JC (2017) miR-15a-3p and miR-16-1-3p negatively regulate Twist1 to repress gastric cancer cell invasion and metastasis. Int J Biol Sci 13(1):122–134CrossRefPubMedPubMedCentral
15.
16.
Shang C, Guo Y, Zhang J, Huang B (2016) Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer. Cancer Chemother Pharmacol 77(5):1061–1067CrossRefPubMed
17.
Lu C, Shan Z, Li C, Yang L (2017) MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother 86:450–456CrossRefPubMed
18.
Cao W, Wei W, Zhan Z, Xie Y, Xiao Q (2016) MiR-1284 modulates multidrug resistance of gastric cancer cells by targeting EIF4A1. Oncol Rep 5:2583–2591CrossRef
19.
Li H, Wang Z, Zhou X, Cheng Y, Xie Z, Manley JL, Feng Y (2013) Far upstream element-binding protein 1 and RNA secondary structure both mediate second-step splicing repression. Proc Natl Acad Sci U S A 110:E2687–E2695CrossRefPubMedPubMedCentral
20.
Olanich ME, Moss BL, Piwnica-Worms D, Townsend RR, Weber JD (2011) Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation. Oncogene 30:77–86CrossRefPubMed
21.
Samarin J, Laketa V, Malz M, Roessler S, Stein I, Horwitz E, Singer S, Dimou E, Cigliano A, Bissinger M, Falk CS, Chen X, Dooley S, Pikarsky E, Calvisi DF, Schultz C, Schirmacher P, Breuhahn K (2016) PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. Hepatology 63(3):813–826CrossRefPubMedPubMedCentral
22.
Sheng H, Ying L, Zheng L, Zhang D, Zhu C, Wu J, Feng J, Su D (2015) Down expression of FBP1 is a negative prognostic factor for non-small-cell lung cancer. Cancer Investig 33(5):197–204CrossRef
23.
Liu ZH, Hu JL, Liang JZ, Zhou AJ, Li MZ, Yan SM, Zhang X, Gao S, Chen L, Zhong Q, Zeng MS (2015) Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. Cell Death Dis 6:e1920CrossRefPubMedPubMedCentral
24.
Hong Y, Shi Y, Shang C, Xue Y, Liu Y (2016) Influence of far upstream element binding protein 1 gene on chemotherapy sensitivity in human U251 glioblastoma cells. Arch Med Sci 12(1):156–162CrossRefPubMedPubMedCentral
25.
Ding Z, Liu X, Liu Y, Zhang J, Huang X, Yang X, Yao L, Cui G, Wang D (2015) Expression of far upstream element (FUSE) binding protein 1 in human glioma is correlated with c-Myc and cell proliferation. Mol Carcinog 54(5):405–415CrossRefPubMed
26.
Yang L, Zhu JY, Zhang JG, Bao BJ, Guan CQ, Yang XJ, Liu YH, Huang YJ, Ni RZ, Ji LL (2016) Far upstream element-binding protein 1 (FUBP1) is a potential c-Mycregulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression. Tumour Biol 37(3):4115–4126CrossRefPubMed
Metadata
Title
MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer
Authors
Danyi Zhao
Yang Zhang
Lei Song
Publication date
01-07-2018
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0263-x

Other articles of this Issue 3/2018

Pathology & Oncology Research 3/2018 Go to the issue

Original Article

Prevalence of Anal Human Papillomavirus Infection in Hungarian Men Who Have Sex with Men

Original Article

Intratumoral Heterogeneity of Frameshift Mutations of GLI1 Encoding a Hedgehog Signaling Protein in Colorectal Cancers

Original Article

Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps

Letter to the Editor

Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management

Original Article

Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis

Original Article

HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits